Follow
Katrina Pollock
Katrina Pollock
Verified email at imperial.ac.uk
Title
Cited by
Cited by
Year
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ...
The Lancet 397 (10269), 99-111, 2021
54152021
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ...
The Lancet 396 (10249), 467-478, 2020
28152020
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four …
M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ...
The Lancet 397 (10277), 881-891, 2021
13572021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial
KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ...
The Lancet 397 (10282), 1351-1362, 2021
7452021
Vaccines for COVID-19
JS Tregoning, ES Brown, HM Cheeseman, KE Flight, SL Higham, ...
Clinical & Experimental Immunology 202 (2), 162-192, 2020
3092020
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ...
The Lancet 398 (10304), 981-990, 2021
2732021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
J Frater, KJ Ewer, A Ogbe, M Pace, S Adele, E Adland, J Alagaratnam, ...
The lancet HIV 8 (8), e474-e485, 2021
2242021
Oxford COVID Vaccine Trial Group Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in …
M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ...
Lancet 397 (10269), 99-111, 2021
1402021
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study
JL Alexander, NA Kennedy, H Ibraheim, S Anandabaskaran, A Saifuddin, ...
The lancet Gastroenterology & hepatology 7 (4), 342-352, 2022
1352022
T-cell immunophenotyping distinguishes active from latent tuberculosis
KM Pollock, HS Whitworth, DJ Montamat-Sicotte, L Grass, GS Cooke, ...
The Journal of infectious diseases 208 (6), 952-968, 2013
1192013
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial
KM Pollock, HM Cheeseman, AJ Szubert, V Libri, M Boffito, D Owen, ...
EClinicalMedicine 44, 2022
1012022
Oxford COVID Vaccine Trial Group Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised …
PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ...
Lancet 396 (10249), 467-478, 2020
712020
Interferon-gamma release assays for tuberculosis: current and future applications
M Thillai, K Pollock, M Pareek, A Lalvani
Expert Review of Respiratory Medicine 8 (1), 67-78, 2014
692014
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre …
JL Alexander, Z Liu, DM Sandoval, C Reynolds, H Ibraheim, ...
The Lancet Gastroenterology & Hepatology 7 (11), 1005-1015, 2022
512022
COVID-19 Genomics UK consortium; AMPHEUS Project
KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ...
Oxford COVID-19 Vaccine Trial Group. Efficacy of ChAdOx1 nCoV-19 (AZD1222 …, 2021
512021
PD-1 Expression and Cytokine Secretion Profiles of Mycobacterium tuberculosis-Specific CD4+ T-Cell Subsets; Potential Correlates of Containment in HIV-TB Co …
KM Pollock, DJ Montamat-Sicotte, L Grass, GS Cooke, MS Kapembwa, ...
PloS one 11 (1), e0146905, 2016
432016
Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support–free days in patients hospitalized with COVID-19: a randomized …
S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, K Fareed, ...
Jama 329 (14), 1183-1196, 2023
332023
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
A Ogbe, M Pace, M Bittaye, T Tipoe, S Adele, J Alagaratnam, PK Aley, ...
JCI insight 7 (7), 2022
332022
Redefining latent tuberculosis
S Sridhar, K Pollock, A Lalvani
Future Microbiology 6 (9), 1021-1035, 2011
312011
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA. 1 and BA. 4/5 variants in patients with inflammatory bowel disease treated with infliximab and …
Z Liu, K Le, X Zhou, JL Alexander, S Lin, C Bewshea, N Chanchlani, ...
The Lancet Gastroenterology & Hepatology 8 (2), 145-156, 2023
252023
The system can't perform the operation now. Try again later.
Articles 1–20